Physician profile
Kovil Ramasamy
NPI 1790765576
$1,951.61
in general payments reported to CMS, 2019-2025
24 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $98.03 · 2021: $15.00 · 2022: $86.00 · 2023: $209 · 2024: $469 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $370.90 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.60 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $169.32 | 2025 | Rezdiffra |
| Ardelyx, INC. | $165.40 | 2023-2025 | Ibsrela |
| Abbvie INC. | $141.45 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $129.16 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $105.85 | 2022-2025 | Simponi, Simponi Aria, Stelara |
| Gilead Sciences, INC. | $73.03 | 2019-2025 | |
| Redhill Biopharma INC. | $55.96 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Laborie Medical Technologies Corp. | $39.95 | 2024 | |
| Novo Nordisk INC | $39.46 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $36.49 | 2025 | Zenpep |
| Celltrion USA INC. | $36.27 | 2025 | Vegzelma |
| Lexicon Pharmaceuticals, INC. | $33.74 | 2020 | |
| Pfizer INC. | $33.44 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $33.22 | 2023-2024 | Ocaliva |
| Braintree Laboratories, INC. | $27.99 | 2024 | Suflave |
| W. L. Gore & Associates, INC. | $24.69 | 2022 | |
| Boston Scientific Corporation | $18.35 | 2019 | |
| Apollo Endosurgery US INC | $17.34 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.00 | 2021 | |
| Allergan, INC. | $15.00 | 2019 | |
| Alfasigma USA, INC. | $14.09 | 2020 | |
| Ironwood Pharmaceuticals, INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kovil Ramasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.